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ABSTRACT
Objective To establish the prevalence and associations 
of systemic antibiotic prescription for impetigo by early-
career general practitioners (GPs) (GP registrars in their 
first 18 months in general practice).
Design A cross-sectional analysis of data from the 
Registrar Clinical Encounters in Training (ReCEnT) study.
Setting ReCEnT is an ongoing multisite cohort study 
of Australian registrars’ in-consultation clinical practice 
across five Australian states.
Participants Registrars participating in ReCEnT from 
2010 to 2017.
Outcome measures Management of impetigo with 
systemic antibiotics.
Results 1741 registrars (response rate 96%) provided 
data from 384 731 problems identified in 246 434 
consultations. Impetigo, on first presentation or follow-
up, was managed in 930 (0.38%, 95% CI 0.35 to 0.40) 
consultations and comprised 0.24% (95% CI 0.23 to 0.26) 
of problems. 683 patients presented with a new diagnosis 
of impetigo of which 38/683 (5.6%) were not prescribed 
antibiotics; 239/683 (35.0%) were prescribed solely topical 
antibiotics; 306/683 (44.8%) solely systemic antibiotics 
and 100/683 (14.6%) both systemic and topical antibiotics. 
The most common systemic antibiotic prescribed was 
cephalexin (53.5%). Variables independently associated 
with prescription of systemic antibiotics were an inner 
regional (compared with major city) location (OR 1.82, 
95% CI 1.06 to 3.13; p=0.028), seeking in-consultation 
information or advice (OR 2.17, 95% CI 1.47 to 3.23; 
p<0.001) and ordering pathology (OR 2.13, 95% CI 1.37 to 
3.33; p=0.01).
Conclusions Australian early-career GPs prescribe 
systemic antibiotics (the majority broad-spectrum) for a 
high proportion of initial impetigo presentations. Impetigo 
guidelines should clearly specify criteria for systemic 
antibiotic prescription and individual antibiotic choice. The 
role of non-antibiotic management and topical antiseptics 
needs to be explored further.
InTRODuCTIOn
Impetigo is a highly contagious superficial 
skin infection caused by Streptococcus pyogenes 
or Staphylococcus aureus.1 2 There are two 
forms, the most common being non-bullous 
impetigo which presents with honey coloured 
crusted erosions or ulcers, typically on the 
face or limbs.1 2 Bullous impetigo is usually 
due to S. aureus2 3 and presents with large fluid 
filled bullae typically in intertriginous areas.4 
Impetigo most commonly affects children 
aged 0–9 years.1 2 5 In Dutch general practice 
the incidence of impetigo presentations is 
20.6 per 1000 person years in the paediatric 
population.6 Impetigo prevalence is highest 
in humid environments and resource-poor 
settings where poverty, overcrowding and 
lack of functioning health hardware such as 
showers and washing machines contribute to 
a high burden of disease.1 2 The median prev-
alence of impetigo across studies of Australian 
remote dwelling Aboriginal and Torres Strait 
Islander populations has been estimated as 
44.5% (IQR 34%–49%),1 with one Aborig-
inal medical service recording an impetigo 
prevalence of 7.5 per 100 consultations for 
localised skin infections.7 At any one time, 
impetigo affects 162 million children glob-
ally and 15 000 Aboriginal and Torres Strait 
Islander children in Australia.1 The prognosis 
for impetigo is good and, although little objec-
tive data is available, self-resolution is thought 
Strengths and limitations of this study
 ► Large sample size.
 ► Data collection from diverse range of practice 
across all Australian states, from metropolitan to 
remote locations.
 ► No measurement of severity of impetigo.
 ► Insufficient power to examine associations of con-
sultations with no antibiotic prescription.
 ► Insufficient power to examine the effect of Aboriginal 
or Torres Strait Islander ethnicity on management 
choice.
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to be common.2 The disease is predominantly managed 
in the community and rarely requires hospitalisation.2 8 
Serious complications such as rheumatic fever, poststrep-
tococcal glomerulonephritis and rheumatic heart disease 
generally only occur in resource-poor areas where S. 
pyogenes is the most common pathogen.2 3 However, given 
its highly contagious nature, children with impetigo are 
usually excluded from school until treatment has been 
commenced, resulting in parental loss of productivity 
and income.9 10 Furthermore, as a common condition 
often treated with antibiotics, impetigo management has 
considerable antibiotic stewardship implications.
Antimicrobial resistance is a serious global threat to 
public health11 12 and has significant repercussions on our 
ability to treat impetigo effectively. Antibiotic misuse in 
treating impetigo may accelerate the emergence of resis-
tant organisms.13 Early-career general practitioners (GPs) 
are a demographic of particular interest in this regard as 
antibiotic prescribing habits established early in practice 
may be long-lasting14 and impetigo is overwhelmingly 
managed in the community.2 8
The aim of this study was to establish the prevalence 
and associations of systemic antibiotic prescription 
(compared with solely topical antibiotic prescription) for 
new presentations of impetigo by early-career GPs (GP 
registrars in their first 18 months of general practice).
MeThODS
Registrar Clinical encounters in Training study
Registrar Clinical Encounters in Training (ReCEnT) 
is an ongoing multisite cohort study of Australian GP 
registrars’ in-consultation clinical practice. Australian 
GP registrars are vocational trainees in general practice. 
These early-career GPs practice with considerable clinical 
autonomy with equivalent prescribing and pathology-or-
dering privileges to experienced colleagues. Participants 
in ReCEnT from 2010 were from five of Australia’s then 
17 Regional Training Providers (RTPs). From 2016 three 
of Australia’s nine Regional Training Organisations in a 
reorganised Australian vocational training programme 
participated. At the time of this analysis, individual regions 
had contributed from two to 16 rounds of six monthly 
data collection. Detailed methodology for ReCEnT has 
been described elsewhere.15 Briefly, registrars undertake 
data collection once per 6-month training term (three 
times in the course of training). Details of 60 consecutive 
office-based consultations are recorded on a paper-based 
Case Report Form. Detailed individual feedback reports 
inform registrars’ reflection on practice.16 Registrars may 
provide informed written consent for their ReCEnT data 
to be also used for research.
Outcome factor
In an analysis including only first presentations of impe-
tigo for which antibiotics were prescribed, the outcome 
factor was ‘systemic antibiotic prescribed’, including 
coprescription with topical systemic antibiotics, versus 
solely topical antibiotic prescribed.
Independent variables
Independent variables related to the registrar, patient, 
practice and consultation.
Registrar-related variables were age, gender, training term, 
place of medical qualification (Australia/international), 
full-time/part-time status and whether they had worked 
at the practice in previous terms.
Patient-related variables were age, gender, Aboriginal or 
Torres Strait Islander status, non-English speaking back-
ground, if the problem/diagnosis was new and whether 
the patient was new to the practice or the registrar.
Practice variables included the training ‘region’, rurality/
urbanicity, practice size (number of GPs), socioeconomic 
status of the practice location, and if the practice routinely 
bulk-bills all patients (resulting in no direct financial cost 
to the patient for the consultation). Practice postcode 
was used to define the Australian Standard Geographical 
Classification-Remoteness Area classification (the degree 
of rurality) of the practice location17 and to define the 
practice location’s Socioeconomic Index for Area Rela-
tive Index of Disadvantage.18
Consultation variables were duration of consultation 
(in minutes), number of diagnoses/problems recorded 
for the consultation, whether pathology or imaging was 
ordered, if specialist referral was made or follow-up was 
organised, and if medication was prescribed. Further 
consultation-related independent variables were educa-
tion-related: whether the registrar sought information, 
advice or assistance for the problem/diagnosis (from 
their supervisor/trainer, from a specialist, or from 
electronic or hard-copy resources) and if the registrar 
generated personal learning goals related to the index 
problem/diagnosis.
Statistical analysis
This was a cross-sectional analysis of data from the 
ReCEnT cohort study. Analysis was at the level of the indi-
vidual problem/diagnosis and performed on 16 rounds 
of data collected from 2010 to 2017. The proportion of 
registrars’ problems/diagnoses that were impetigo and 
the proportion of consultations involving an impetigo 
problem/diagnosis were calculated, with 95% CIs. For 
first presentations of impetigo that were prescribed anti-
biotics, univariate and multivariable logistic regression 
was conducted with outcome factor ‘systemic antibiotic 
prescribed’ versus ‘solely topical antibiotic prescribed’. 
Logistic regression was used within the generalised esti-
mating equations framework to account for repeated 
measures within registrars, an exchangeable working 
correlation structure was assumed.
Covariates with a univariate p value <0.20 in univariate 
analysis were included in the multiple regression model 
which was then assessed for model reduction. Covariates 
which were no longer significant (at p<0.2) were tested 
for removal from the model, and were removed only if 
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Figure 1 Prevalence and antibiotic management of impetigo.
their removal did not change other coefficient estimates 
by >10%. In post-hoc analyses, association of information 
or advice-seeking (hard copy/electronic or supervisor) 
with systemic antibiotic prescription was tested with χ2 
analyses. Statistical analyses were programmed using 
STATA V.14.0 and SAS V.9.4. P values <0.05 were consid-
ered statistically significant.
Patient and public involvement
Patient and public were not involved in the design, 
conduct or reporting of research.
ReSulTS
A total of 1741 GP trainees (response rate 96%) contrib-
uted data for 384 731 patient problems, from 246 434 
consultations. Impetigo was managed in 930 of these 
problems/diagnoses (930/384 731, 0.24% (95% CI 
0.23 to 0.26)) and comprised 0.38% of all consultations 
(930/246 434, 95% CI 0.35 to 0.40).
Of 683 patients presenting with a new diagnosis of 
impetigo, 38/683 (5.6%) were not prescribed antibiotics; 
239/683 (35.0%) were prescribed solely topical antibi-
otics; 306/683 (44.8%) were prescribed solely systemic 
antibiotics; and 100/683 (14.6%) were prescribed both 
systemic and topical antibiotics (figure 1).
Univariate associations of systemic antibiotic prescribing 
are summarised in table 1. In multivariate analysis, seeking 
in-consultation information or assistance, ordering 
pathology, and an inner regional (compared with a major 
city) practice location were significantly associated with 
prescribing systemic antibiotics (table 2). Patients aged 
15–34 years (compared with age 65 or more) were more 
likely to be managed with systemic antibiotics. No vari-
ables were removed from the multiple regression model.
Cephalexin was the most frequently prescribed oral 
antibiotic (215/406, 53.0%), followed by di/flucloxa-
cillin (154/406, 37.9%) (figure 2). Age was recorded in 
404/406 consultations involving systemic antibiotics. In 
children under 8 years old, 112/193 (58.0%) of systemic 
antibiotics prescribed were cephalexin, 60/193 (31.1%) 
were flucloxacillin while no dicloxacillin (which has no 
subsidised liquid formulation in Australia) was prescribed. 
In patients older than 8 years, 101/211 (47.9%) were 
prescribed cephalexin, 76/211 36.0% were prescribed 
flucloxacillin and 18/211 8.5% were prescribed dicloxa-
cillin. The ratio of cephalexin to influenza/dicloxacillin 
prescribed was1.9:1 in under 8 years and 1.1:1 in older 
than 8 years.
Systemic antibiotic prescription that did not adhere to 
authoritative Australian guidelines occurred in 29/406 
(7.1%) consultations, with amoxicillin and amoxicillin/
clavulanate being most commonly prescribed. The 
most frequently prescribed topical antibiotic was mupi-
rocin (329/339, 97.1%) (figure 2). Of topical antibiotic 
choices, 329/339 (97.1%) were guideline-consistent.
DISCuSSIOn
Systemic versus topical antibiotic prescribing
Australian early-career GPs largely managed impetigo in 
accordance with current Australian guidelines (box 1). 
However, a relatively high proportion of initial impe-
tigo presentations (406/683, 59.4%) were managed with 
systemic antibiotics. Only 35.0% received solely topical 
antibiotics and only 5.6% were managed without antibi-
otics. This contrasts with a Dutch study where only 14% 
of patients with impetigo were prescribed oral antibiotics, 
while 64% were managed with topical antibiotics and 22% 
were managed without antibiotics (including 3% managed 
with antiseptics).6 This 2001 study also showed a trend of 
increasing topical antibiotic use compared with 1987 data 
which had found 43% topical, 31% oral and 11% anti-
septic use. This difference in antibiotic prescribing may 
be attributable to guideline differences: at the time of 
this study Dutch guidelines encouraged the use of topical 
antibiotics first line, irrespective of impetigo severity, and 
also encouraged non-antibiotic treatment for limited 
lesions.6 The Australian guidelines currently recommend 
topical antibiotics for ‘localised skin sores’ and systemic 
antibiotics only for ‘multiple skin sores or recurrent infec-
tion’ but do not define ‘localised’ or ‘multiple’ (box 1). 
This lack of definition may explain high proportions of 
systemic antibiotic prescribing in our Australian early-ca-
reer GPs. New Zealand (NZ) guidelines provide clear 
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Table 1 Characteristics of patient presenting with impetigo with antibiotic prescribed
Variable Class Topical only Systemic±topical P value
Patient variables
  Patient age group
  (n=639)
0–14 180 (77%) 294 (73%) 0.018
15–34 27 (11%) 73 (18%)
35–64 19 (8%) 33 (8%)
65+ 9 (4%) 4 (1.0%)
  Patient gender (n=623) Male 117 (51%) 187 (47%) 0.35
Female 111 (49%) 208 (53%)
  Aboriginal or Torres Strait 
Islander (n=604)
No 213 (96%) 362 (95%) 0.42
Yes 8 (4%) 21 (5%)
  NESB (n=605) No 213 (96%) 374 (98%) 0.19
Yes 9 (4%) 9 (2%)
  Patient/practice status 
(n=631)
Existing patient 52 (22%) 75 (19%) 0.60
New to practice 18 (8%) 39 (10%)
New to trainee 166 (70%) 281 (71%)
Trainee variables
  Trainee gender
  (n=645)
Male 105 (44%) 174 (43%) 0.84
Female 134 (56%) 232 (57%)
  Trainee FT or PT (n=622) Part-time 54 (23%) 69 (18%) 0.12
Full-time 178 (77%) 321 (82%)
  Term (n=645) Term 1 98 (41%) 173 (43%) 0.20
Term 2 73 (31%) 140 (34%)
Term 3 68 (28%) 93 (23%)
  Worked at practice 
previously (n=639)
No 186 (78%) 303 (76%) 0.57
Yes 52 (22%) 98 (24%)
  Qualified as doctor in 
Australia (n=641)
No 35 (15%) 95 (24%) 0.020
Yes 202 (85%) 309 (76%)
  Trainee age Mean (SD) 32 (6) 33 (7) 0.20
Practice variables
  Practice size (n=624) Small 75 (33%) 141 (36%) 0.46
Large 155 (67%) 253 (64%)
  Practice routinely bulk bills
  (n=640)
No 206 (88%) 343 (85%) 0.47
Yes 29 (12%) 62 (15%)
  Rurality (n=644) Major city 148 (62%) 191 (47%) 0.002
Inner regional 46 (19%) 133 (33%)
Outer regional remote 44 (18%) 82 (20%)
  Region (n=645) Region 1 84 (35%) 146 (36%) 0.26
Region 2 12 (5%) 27 (7%)
Region 3 28 (12%) 58 (14%)
Region 4 94 (39%) 130 (32%)
Region 5 10 (4%) 30 (7%)
Region 6 11 (5%) 15 (4%)
  SEIFA index Mean (SD) 6 (3) 6 (3) 0.22
Consultation variables
  Sought help any source
  (n=645)
No 176 (74%) 237 (58%) <0.001
Yes 63 (26%) 169 (42%)
Continued
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Variable Class Topical only Systemic±topical P value
  Consultation duration Mean (SD) 14 (6) 14 (6) 0.60
  Number of problems Mean (SD) 1 (1) 1 (1) 0.030
Consultation outcome variables
  Pathology ordered (n=645) No 210 (88%) 308 (76%) 0.001
Yes 29 (12%) 98 (24%)
  Learning goals generated
  (n=614)
No 192 (85%) 321 (83%) 0.27
Yes 33 (15%) 68 (17%)
  Follow-up ordered (n=645) No 151 (63%) 243 (60%) 0.38
Yes 88 (37%) 163 (40%)
  Imaging ordered (n=645) No 239 (100%) 405 (99.8%) 1.00
P values from unadjusted generalised estimating equations analysis.
Region is derived from former Regional Training Provider and current Regional Training Organisation geographic footprints.
FT, full time;NESB, non-English speaking background; PT, part time;SEIFA, Socioeconomic Indexes of Areas.
Table 1 Continued
Table 2 Associations with a new diagnosis of impetigo with systemic±topical antibiotics prescribed (compared with topical 
only)
Variable Class
Univariate OR 
(95% CI) P value Adjusted OR (95% CI) P value
Patient, registrar and practice variables
  Patient age group
  (Referent: 15–34)
0–14 0.61 (0.38 to 0.98) 0.043 0.58 (0.34 to 1.02) 0.060
35–64 0.64 (0.32 to 1.28) 0.20 0.74 (0.32 to 1.69) 0.48
65+ 0.15 (0.04 to 0.53) 0.003 0.08 (0.01 to 0.44) 0.004
  NESB Yes 0.55 (0.22 to 1.35) 0.19 0.62 (0.20 to 1.89) 0.40
  Registrar FT or PT Part-time 0.71 (0.47 to 1.09) 0.12 0.79 (0.50 to 1.28) 0.35
  Qualified as doctor in 
Australia
Yes 0.58 (0.36 to 0.92) 0.020 0.68 (0.38 to 1.22) 0.19
  Rurality
  (Referent: major city)
Inner regional 2.22 (1.43 to 3.45) <0.001 1.82 (1.06 to 3.13) 0.028
Outer regional remote 1.45 (0.92 to 2.27) 0.11 1.25 (0.74 to 2.08) 0.41
  Number of problems   0.78 (0.62 to 0.97) 0.030 0.89 (0.69 to 1.15) 0.385
Consultation variables
  Sought help any 
source
Yes 2.13 (1.49 to 3.03) <0.001 2.17 (1.47 to 3.23) <0.001
Consultation outcome variables
  Pathology ordered Yes 2.13 (1.37 to 3.33) 0.001 1.89 (1.16 to 3.03) 0.010
FT, full time; NESB, non-English speaking background; PT, part time.
definitions, recommending oral antibiotics for systemic 
symptoms (fever, malaise), high risk of complications, not 
responding to first line treatment or where there are more 
than three lesions.19 20 While international guidelines 
display congruence in recommending oral antibiotics 
for systemic symptoms and failure of first-line treatment; 
definitions of severity employ vague terms such as ‘local-
ised, extensive, numerous lesions or widespread’3 20–24 
(table 3). This lack of clarity allows room for significant 
subjectivity and variation in clinical decision-making, 
potentially compromising antibiotic stewardship.
Topical antibiotics for localised lesions are as effica-
cious as oral antibiotics25 and thus preferred by many 
guidelines because of their lower potential for antimi-
crobial resistance and systemic side effects.26 However 
with increasing resistance to topical antibiotics27–34 and 
increasing community methicillin resistant S. aureus 
rates,35–37 antibiotic guidelines should reflect local resis-
tance profiles.25 38 NZ guidelines differ in their response 
to topical resistance by discouraging the use of topical 
antibiotics and instead recommending good skin hygiene 
and topical antiseptics19 20 (table 3).
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Figure 2 Systemic antibiotic prescription.
Box 1 Australian therapeutic guidelines for impetigo3
For localised skin sores, recommendation is:
 ► Mupirocin 2% ointment.
For multiple impetigo lesions or recurrent infection, recommendation is:
 ► Di/flucloxacillin.
Cephalexin, though, may be used for patients with non-immediate hy-
persensitivity to penicillins or in children due to greater tolerability and 
better palatability of liquid formula.
For patients with anaphylaxis to penicillins, the recommendation is:
 ► Trimethoprim+sulfamethoxazole.
 The Therapeutic Guidelines make specific reference to different man-
agement recommendations for impetigo in remote Aboriginal and Torres 
Strait Islander communities: “First line treatment is trimethoprim plus 
sulfamethoxazole or intramuscular benzathine penicillin; topical antibi-
otics are not recommended”.
experience levels
A factor that may contribute to the comparatively high 
proportion of systemic antibiotic use is the difference 
in level of experience between Australian GP registrars 
(early in their GP careers) and the established GPs 
involved in the 2001 Dutch study.6 Previous studies have 
shown that GP registrars find dermatological presenta-
tions challenging despite having adequate exposure to 
dermatological cases.39 Additionally, registrars in a qual-
itative study reported prescribing antibiotics as ‘playing it 
safe’ early in their clinical experience but being less likely 
to prescribe with increasing time and confidence.40 Our 
early-career GPs who prescribed systemic antibiotics were 
more likely to seek information or advice either from 
their supervisor or from guidelines. As we do not have 
a measure of impetigo severity in our data it is difficult 
to ascertain whether seeking advice from a supervisor is 
a risk factor for prescribing antibiotics, or whether this 
reflects appropriate practice -information/advice being 
sought for more severe disease warranting antibiotics— 
by registrars. Information-seeking may also have been to 
check dosing, particularly in paediatric patients. Ensuring 
adherence to appropriate treatment and responsible 
prescribing of antimicrobials in this cohort is important 
as GP registrars in Australia have the same prescribing 
rights as established GP’s and work independently, 
with direct supervision only when requested. There is 
evidence that antibiotic prescribing patterns developed 
earlier in GPs’ careers remain stable over time.14 There-
fore, instilling values of antimicrobial stewardship and 
rational prescribing in early-career doctors has significant 
implications for future practice.
Dual prescription of topical and systemic antibiotics
Australian early career GPs prescribed both topical and 
systemic antibiotics in 100/683 (14.6%) of new impe-
tigo cases, despite there being no evidence to support 
combined use25 and no recommendation in guide-
lines.3 20–24 This may indicate confusion in the manage-
ment of impetigo which may be avoided if combined 
treatment were specifically addressed in guidelines.
Broad spectrum antibiotic prescribing
Despite di/flucloxacillin being recommended as first 
line systemic antibiotic for treatment of impetigo,3 the 
most frequently prescribed antibiotic was cephalexin. It 
is unlikely that penicillin allergy is the sole explanation.41 
Australian guidelines for impetigo comment that ceph-
alexin may be used instead of flucloxacillin for children 
‘due to greater tolerability and better palatability of the 
liquid formulation’.3 Though medication compliance is 
important, this ‘escape’ clause in Australia may foster a 
culture that allows unnecessary broad-spectrum antibiotic 
prescription simply because it is ‘easier’ than using appro-
priate narrow-spectrum treatment. We found a prefer-
ence for cephalexin rather than di/flucloxacillin even in 
patients older than 8 years. In contrast, most European 
guidelines and the NZ guidelines do not recommend 
cephalexin.20–22 24 UK figures show less than 2% of ceph-
alexin prescriptions were for skin infections and cepha-
lexin was used to treat only 1% of impetigo cases, with 
flucloxacillin usually prescribed.42 This perhaps indi-
cates that perceived barriers to compliance can be over-
come. In addition to modifying guidelines, clinicians in 
Australia could work collaboratively with pharmaceutical 
companies to develop more palatable narrow spectrum 
antibiotics options.
Topical antiseptics
A 2012 Cochrane review found insufficient evidence 
to support the use of topical antiseptics for impetigo.25 
Pooling of two low-quality studies43 44 with a total of 292 
participants showed marginal superiority of topical anti-
biotics compared with antiseptics (risk ratio (RR) 1.15 
95% CI 1.01 to 1.32). Guidelines appear to differ in their 
interpretation of this paucity of evidence, either stating 
antiseptics are not recommended,22–24 encouraging their 
use,20 or not mentioning them at all3 (table 3). Only 
3.5% of cases in our study were managed without anti-
biotics and given concerns regarding growing resistance 
to topical and oral antibiotics used for impetigo, further 
studies to clarify the efficacy and potential role of topical 
antiseptics are required. Given the modest consequences 
of failed treatment, recommending the use of topical 
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Table 3 Comparison of international guidelines for management of impetigo
Country, year
Advice on 
antiseptics
Topical antibiotic 
indications and 
recommendations
Oral antibiotic indications and 
recommendations
Skin swab 
indications
Australia,
20173
Not specified. ‘Localised lesions’: 
Mupirocin.
‘Remote setting’:
Topical treatment not 
recommended.
‘Multiple lesions, recurrent infection’: 
Di/flucloxacillin.
Penicillin allergy:
Cephalexin or trimethoprim 
+sulfamethoxazole.
‘Remote settings’:
Benzathine penicillin or trimethoprim-
sulfamethoxazole.
Only for severe 
disease or no 
response to 
empirical treatment.
UK, 2015 22 Antiseptics should 
not be used due 
to risk of local 
reaction, and not 
recommended due to 
lack of evidence.
‘Localised lesions’:
Fusidic acid.
Mupirocin reserved for 
known MRSA.
Retapamulin second 
line as more costly than 
fusidic acid.
‘Extensive areas’:
Flucloxacillin.
Penicillin allergy:
Clarithromycin or erythromycin.
Empirical treatment 
failure.
Netherlands, 
2017 24
Use of antiseptics or 
disinfectants is not 
recommended.
‘First choice’:
Fusidic acid.
‘If insufficient response’:
Flucloxacillin.
Penicillin allergy clarithromycin or 
clindamycin.
Additional 
diagnostics not 
needed unless:
Increased risk 
Methicillin-resistant 
Stpahylococcal 
aureus (MRSA) or 
screening for S. 
aureus carrier or 
suspected abscess.
New Zealand, 
2017 20
For localised lesions 
(≤3)’: hydrogen 
peroxide 1% or 
povidone-iodine 
10%.
‘For localised infection, 
second line to topical 
antiseptics’: Fusidic acid
Not first line as high 
rates of resistance.
Extensive, widespread infection; 
systemic symptoms’:
Flucloxacillin.
‘Penicillin allergy or MRSA’:
Trimethoprim+sulfamethoxazole or 
erythromycin.
Not specified.
USA,
201423
There is insufficient 
evidence to 
recommend topical 
disinfectants for 
impetigo.
Topical treatment 
recommended over oral:
Mupirocin or 
retapamulin.
‘Numerous lesions or outbreaks’:
Dicloxacillin or cephalexin
‘MRSA suspected or confirmed’: 
Doxycycline, clindamycin or 
trimethoprim +sulfamethoxazole.
Recommended but 
may treat without if 
typical case.
antiseptics for limited lesions may be reasonable as first 
line management.
Strengths and limitations
ReCEnt study data includes a large sample of GP regis-
trars from across diverse regions of Australia, from major 
cities to very remote areas. It is the largest database of 
clinical encounters of early-career GPs in Australia.
There are limitations to the analysis and interpretation 
of these data. We do not have data on severity, including 
number of lesions, or of history of recurrent disease. No 
system for grading severity was used in this study, which 
is reflective of the lack of severity criteria seen in most 
guidelines (table 3). With this lack of consensus in guide-
lines there would have been little evidence base for a 
severity grading system in our study. There was insuffi-
cient power to examine associations of consultations with 
no antibiotic prescription. The low number of Aboriginal 
or Torres Strait Islander patients (4%) limited our power 
to measure the effect of this important patient demo-
graphic on management choice.
Implications for future research
Concerns regarding antimicrobial resistance justify inves-
tigation into alternative topical treatments.45 Further 
investigation into topical antiseptics could bring greater 
congruence to international guidelines and potentially 
encourage non-antibiotic treatment of impetigo, partic-
ularly for single or limited lesions. Despite evidence 
that complementary treatments such as tea tree oil are 
effective against S. aureus,46 objective evidence for use 
in treating impetigo is lacking and they are currently 
not recommended in guidelines. However, scarce data 
for non-antibiotic treatments is promising and warrants 
further investigation.25 Novel topical antibiotic agents 
such as ozenoxacin and retapamulin have been shown 
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to be effective in treating impetigo,47 48 but should be 
reserved for resistant strains until there is further research 
in this area.
COnCluSIOn
Appropriate use of antibiotics is of utmost importance 
in the management of impetigo. Our findings show 
that Australian early-career GPs use more systemic anti-
biotics and more broad-spectrum antibiotics compared 
with colleagues in other settings. More clarity of guide-
lines, including criteria for severity of disease, could steer 
towards more appropriate use. Exploration of non-antibi-
otic management options is an important area for future 
research.
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